CAMBRIDGE, Mass.: Vyome Holdings, Inc. (Nasdaq: HIND), a clinical-stage healthcare holding company, announced the acquisition of substantially all assets of Oculo, Inc., an artificial intelligence startup spun out of the Massachusetts Institute of Technology (MIT).
This strategic move marks Vyome’s entry into digital health with the creation of a new business unit focused on developing an AI psychiatrist for inflammation.
Vyome Holdings to Develop AI Psychiatrist Targeting Inflammation
As part of the transaction, Vyome will leverage Oculo’s AI assets to build an AI psychiatrist trained on datasets from the US and India.
Also Read: Prosper AI Secures USD 5M to Solve Healthcare’s USD 450B Administrative Crisis
The initiative aims to diagnose and help treat systemic inflammation by identifying behavioral drivers and biomarkers.
The program will be overseen by a newly formed Vyome Board of Directors AI subcommittee, which includes Krishna Gupta, Mohanjit Jolly, and Stash Pomichter – all MIT alumni with expertise in AI and healthcare.
“Innovation in AI offers an unprecedented opportunity to address inflammation, which remains one of the world’s biggest health challenges,” said Stash Pomichter, Director at Vyome.
“Our vision is an AI psychiatrist that reduces dependence on steroids by targeting behavioral and biological factors driving systemic inflammation.”
Creating a New Therapeutic Category
Vyome aims to establish a novel therapeutic category at the intersection of mental health, psychoneuroimmunology, and digital health. Initial commercialization is planned for the US and India.
Also Read: CitiusTech Knewron Debuts as AI Platform to Accelerate Healthcare Innovation
Oculo’s existing research, including its work on biomarkers such as “brain burn,” will serve as a critical foundation for Vyome’s AI-driven initiatives.
Alay Shah, Founder of Oculo, noted, “We launched Oculo to quantify the workings of the mind through AI. Vyome is now carrying forward that vision to address inflammation with human-in-the-loop AI.”
Vyome Maintains Focus on Core Biotech Assets
The acquisition of Oculo does not impact Vyome’s core biotech programs, which remain fully funded through 2026. Alongside its AI psychiatrist efforts, Vyome continues to advance biotech solutions targeting inflammation.
Commenting on market potential, Mohanjit Jolly, Vyome Director and Partner at Iron Pillar, said, “The digital therapeutics market could surpass $100 billion in the next decade. By using AI to reduce reliance on harmful drugs and biologics, Vyome is positioned to transform healthcare outcomes.”
